Genentech Inc.’s third-quarter profit rose 2% to...
- Share via
Genentech Inc.’s third-quarter profit rose 2% to $5.3 million. Revenue advanced 83% to $245.3 million. The San Francisco biotechnology company had predicted a disappointing performance because of slower-than-expected sales of its heart drug TPA, which it has decided to stop producing until 1989.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
